PacBio and Verily Health have announced a multi-year collaboration to combine PacBio's advanced HiFi long-read sequencing technology with Verily's AI and data platform, Verily Pre. This integration aims to create AI-ready clinico-genomic datasets by linking detailed genomic data with real-world clinical information at a large scale. The partnership addresses challenges in biomedical AI by making complex genetic data more accessible and usable, which could accelerate discoveries in neurology, oncology, rare diseases, and other critical health areas. Over time, the collaboration plans to expand support for large-scale genomic programs across research, biopharma, and population health, fostering innovation in precision medicine.
PacBio and Verily Health's multi-year collaboration to scale long-read genomics for biomedical AI is the subject, with Pluang's Health-sector market snapshot as of Oct 19, 2026 20:02 WIB: of 150 priced Health-sector US stocks tradable on Pluang, 62 rose and 66 fell today. Notable movers include RXRX at USD 3.53 with a 1-day change of +1.88% and a typical hold time on Pluang of 21 days, TXG at USD 71.10 (+1.77%, 92 days hold), and SNY at USD 39.90 (-1.75%, 94 days hold).
Disc Medicine's stock surged 38% following positive Phase 3 trial results for its drug bitopertin, which showed efficacy and safety in treating erythropoietic protoporphyria. BMO Capital raised its price target from $100 to $120 and maintained an Out...
Qualcomm executive Ann C. Chaplin sold 1,827 shares of the company's stock for $319,268.25 under a Rule 10b5-1 trading plan, reducing her holdings by 6.62%. Qualcomm's stock price recently traded below its 50-day and 200-day moving averages, signalin...
BOK Financial is set to announce its Q3 2026 earnings after market close on October 19, with analysts forecasting earnings per share between $2.52 and $2.54 and revenue near $571 million. The company has a strong history of surpassing earnings estima...
AIBotics has completed the acquisition of NovaCore Labs' assets from PlayJamaica Limited, gaining technology, software, drones, mapping equipment, and customer contracts. This move expands AIBotics' platform in Jamaica and the Caribbean, enhancing AI...
EyePoint's stock dropped sharply after its DURAVYU treatment did not meet the primary endpoint in a Phase 3 trial for wet age-related macular degeneration (wet AMD). Although DURAVYU showed some vision improvement and reduced the need for additional ...
